117 related articles for article (PubMed ID: 6613161)
1. Human metabolism of antipyrine labelled with 14C in the pyrazolone ring or in the N-methyl group.
Uchino H; Inaba T; Kalow W
Xenobiotica; 1983 Mar; 13(3):155-62. PubMed ID: 6613161
[TBL] [Abstract][Full Text] [Related]
2. Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation.
Engel G; Hofmann U; Heidemann H; Cosme J; Eichelbaum M
Clin Pharmacol Ther; 1996 Jun; 59(6):613-23. PubMed ID: 8681486
[TBL] [Abstract][Full Text] [Related]
3. Studies on the different metabolic pathways of antipyrine in rats: influence of phenobarbital and 3-methylcholanthrene treatment.
Danhof M; Krom DP; Breimer DD
Xenobiotica; 1979 Nov; 9(11):695-702. PubMed ID: 119355
[TBL] [Abstract][Full Text] [Related]
4. High-performance liquid chromatographic method for the determination of the three main oxidative and 3-carboxylic antipyrine metabolites in human urine.
Palette C; Cordonnier P; Naline E; Advenier C; Pays M
J Chromatogr; 1991 Jan; 563(1):103-13. PubMed ID: 2061375
[TBL] [Abstract][Full Text] [Related]
5. The disposition of antipyrine and its metabolites in young and elderly healthy volunteers.
Posner J; Danhof M; Teunissen MW; Breimer DD; Whiteman PD
Br J Clin Pharmacol; 1987 Jul; 24(1):51-5. PubMed ID: 3620285
[TBL] [Abstract][Full Text] [Related]
6. Antipyrine metabolism in man: simultaneous determination of norantipyrine and 4-hydroxyantipyrine in urine by gas chromatography.
Inaba T; Fischer NE
Can J Physiol Pharmacol; 1980 Jan; 58(1):17-21. PubMed ID: 7378903
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of enzyme induction on antipyrine metabolite formation.
Danhof M; Verbeek RM; van Boxtel CJ; Boeijinga JK; Breimer DD
Br J Clin Pharmacol; 1982 Mar; 13(3):379-86. PubMed ID: 7059438
[TBL] [Abstract][Full Text] [Related]
8. Quinidine does not alter antipyrine metabolism.
Bowles SK; Cardozo L; Edwards DJ
J Clin Pharmacol; 1990 Mar; 30(3):267-71. PubMed ID: 2312782
[TBL] [Abstract][Full Text] [Related]
9. Antipyrine clearance and metabolism in patients with psoriasis.
Kubota K; Ishizaki T; Chiba K; Takagi A; Nakagawa A; Nakamura K
Br J Clin Pharmacol; 1986 Oct; 22(4):455-62. PubMed ID: 3768257
[TBL] [Abstract][Full Text] [Related]
10. Antipyrine metabolism is not affected by terbinafine, a new antifungal agent.
Seyffer R; Eichelbaum M; Jensen JC; Klotz U
Eur J Clin Pharmacol; 1989; 37(3):231-3. PubMed ID: 2612536
[TBL] [Abstract][Full Text] [Related]
11. Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis.
Teunissen MW; Spoelstra P; Koch CW; Weeda B; van Duyn W; Janssens AR; Breimer DD
Br J Clin Pharmacol; 1984 Nov; 18(5):707-15. PubMed ID: 6508980
[TBL] [Abstract][Full Text] [Related]
12. Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time.
Danhof M; van Zuilen A; Boeijinga JK; Breimer DD
Eur J Clin Pharmacol; 1982; 21(5):433-41. PubMed ID: 7075648
[TBL] [Abstract][Full Text] [Related]
13. The effect of intravenous pretreatment with small liposomes on the pharmacokinetics and metabolism of antipyrine in rabbits.
Badiola N; Al-Angary AN; Halbert GW
J Pharm Pharmacol; 1992 Apr; 44(4):366-8. PubMed ID: 1355554
[TBL] [Abstract][Full Text] [Related]
14. Antipyrine metabolite kinetics in healthy human volunteers during multiple dosing of phenytoin and carbamazepine.
Shaw PN; Houston JB; Rowland M; Hopkins K; Thiercelin JF; Morselli PL
Br J Clin Pharmacol; 1985 Dec; 20(6):611-8. PubMed ID: 4091993
[TBL] [Abstract][Full Text] [Related]
15. The effect of verapamil on antipyrine pharmacokinetics and metabolism in man.
Bach D; Blevins R; Kerner N; Rubenfire M; Edwards DJ
Br J Clin Pharmacol; 1986 Jun; 21(6):655-9. PubMed ID: 3741715
[TBL] [Abstract][Full Text] [Related]
16. Antipyrine metabolite formation and excretion in patients with chronic renal failure.
Teunissen MW; Kampf D; Roots I; Vermeulen NP; Breimer DD
Eur J Clin Pharmacol; 1985; 28(5):589-95. PubMed ID: 4043202
[TBL] [Abstract][Full Text] [Related]
17. Antipyrine metabolites in two populations.
Inaba T; Uchino H; Kadar D; Kalow W
Res Commun Chem Pathol Pharmacol; 1981 May; 32(2):235-44. PubMed ID: 7244362
[TBL] [Abstract][Full Text] [Related]
18. Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans.
Abernethy DR; Egan JM; Dickinson TH; Carrum G
J Pharmacol Exp Ther; 1988 Mar; 244(3):994-9. PubMed ID: 3252045
[TBL] [Abstract][Full Text] [Related]
19. Influence of mild thyroid dysfunction on antipyrine clearance and metabolite formation in man.
Teunissen MW; van der Veen EA; Doodeman PJ; Breimer DD
Eur J Clin Pharmacol; 1984; 27(1):99-103. PubMed ID: 6489432
[TBL] [Abstract][Full Text] [Related]
20. Effect of spironolactone on antipyrine metabolism in calves.
Janus K; Suszycka J
Res Vet Sci; 1996 Jul; 61(1):87-8. PubMed ID: 8819201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
